high
consequ
human
pathogen
virus
must
handl
biosafeti
level
must
render
noninfecti
util
molecular
immunolog
applic
lower
biosafeti
level
evalu
psoraleninactiv
arena
bunya
corona
filo
flaviand
orthomyxovirus
suitabl
antigen
immunolog
process
templat
revers
transcript
pcr
sequenc
method
viru
inactiv
use
psoralen
molecul
appear
broad
applic
rna
virus
leav
particl
rna
treat
viru
intact
render
viru
noninfecti
one
challeng
face
research
biocontain
laboratori
materi
move
higher
level
biocontain
lower
biocontain
level
biosafeti
level
bsl
must
proven
steril
undergo
valid
verifi
method
agent
inactiv
involv
inocul
portion
materi
biolog
agent
contain
sampl
move
medium
capabl
support
growth
target
organ
evalu
presenc
agent
suffici
incub
time
pass
allow
viabl
organ
present
amplifi
detect
level
ie
coloni
plate
turbid
broth
media
assay
use
detect
viabl
organ
vari
depend
target
agent
human
pathogen
virus
steril
test
involv
process
begin
inocul
portion
sampl
interest
permiss
cell
cultur
line
depend
sampl
may
contain
materi
toxic
cell
cultur
line
requir
extend
incub
ensur
detect
quantiti
viru
present
addit
round
cell
cultur
amplif
may
employ
suffici
time
pass
allow
amplif
surviv
viru
detect
assay
plaqu
assay
immunomicrotitr
immunofluoresc
perform
detect
viabl
agent
indic
process
inactiv
insuffici
sampl
may
move
lower
biocontain
area
steril
test
take
time
excess
three
week
depend
viru
research
sought
inactiv
method
valid
support
reduc
time
sampl
move
lower
biocontain
level
sens
inactiv
refer
use
test
valid
method
known
suffici
repeatedli
render
sampl
steril
materi
virus
wwwmdpicomjournalvirus
inactiv
use
welldocu
valid
inactiv
procedur
may
move
lower
biocontain
level
transport
dispos
without
steril
test
exampl
wide
accept
inactiv
method
autoclav
process
perform
correctli
equip
maintain
oper
within
normal
paramet
suitabl
verif
full
effect
cycl
biolog
indic
machin
readout
materi
subject
process
consid
steril
steril
test
perform
everi
sampl
undergo
autoclav
method
dispos
variou
formul
formaldehyd
wide
util
inactiv
viru
prepar
howev
like
autoclav
method
render
sampl
unus
molecular
genom
andor
immunolog
method
anoth
wide
accept
method
agent
inactiv
use
reagent
contain
phenol
chaotrop
salt
guanidin
isothiocyan
guanidin
thiocyan
commerci
avail
trizol
ls
tripur
reagent
respect
inactiv
viral
sampl
use
trizol
ls
inactiv
viral
agent
standard
accept
method
number
institut
decad
howev
actual
steril
test
data
support
posit
difficult
obtain
complic
interpret
mainli
due
toxic
natur
trizol
lstripur
reagent
cell
cultur
line
trizol
ls
compris
phenol
extrem
caustic
organ
solvent
guanidin
isothiocyan
chaotrop
salt
denatur
macromolecul
dna
rna
protein
convent
method
confirm
steril
begin
place
portion
inactiv
sampl
cell
cultur
layer
provid
opportun
surviv
viru
infect
grow
suffici
quantiti
detect
observ
cytopath
effect
cpe
detect
method
toxic
trizol
ls
undilut
treat
viral
sampl
caus
almost
immedi
death
cell
cultur
layer
use
steril
test
previou
studi
dilut
trizol
lsinactiv
sampl
still
observ
tissu
cultur
cell
death
steril
test
studi
neg
presenc
viral
agent
must
note
test
could
perform
treat
sampl
dilut
mani
thousand
fold
longer
toxic
tissu
cultur
cell
possibl
remain
scenario
presenc
small
number
surviv
viru
would
elud
detect
attempt
made
remov
trizol
ls
prior
steril
test
method
dialysi
spin
column
filtrat
investig
caustic
natur
reagent
problemat
dialysi
materi
rate
small
percentag
phenol
well
concentr
present
trizol
lsinactiv
sampl
membran
filter
resist
phenol
nevertheless
wide
accept
trizol
ls
method
biocontain
laboratori
standard
inactiv
virus
base
histor
data
preced
known
mechan
action
inactiv
agent
investig
properti
psoralen
led
realiz
group
compound
might
provid
method
inactiv
viral
agent
preserv
structur
need
antigen
activ
nucleic
acid
molecular
genom
analysi
psoralen
small
photoreact
compound
freeli
penetr
phospholipid
bilay
intercal
nucleic
acid
pyrimidin
residu
caus
crosslink
inactiv
via
inhibit
replic
follow
exposur
uva
radiat
psoralen
appear
interact
protein
inactiv
virus
psoralen
may
leav
immunogen
surfac
epitop
intact
photocrosslink
properti
psoralen
exploit
inactiv
microorgan
blood
suppli
treatment
skin
disord
inactiv
viral
pathogen
prior
organ
transplant
inactiv
virus
potenti
vaccin
neither
exposur
psoralen
alon
exposur
longwav
uv
light
alon
suffici
inactiv
dna
rna
virus
incub
psoralen
absenc
uv
light
caus
observ
cell
death
previous
use
dengu
viru
repres
posit
singlestrand
rna
ssrna
genom
viru
demonstr
inactiv
viru
psoralen
compound
aminomethyltrioxsalen
amt
inactiv
dengu
viru
retain
abil
bind
panel
five
monoclon
antibodi
specif
envelop
protein
elicit
tcell
respons
vaccin
mice
similar
live
noninactiv
viru
extend
inactiv
method
multipl
viru
famili
examin
suitabl
psoraleninactiv
viral
rna
molecular
biolog
applic
revers
transcript
pcr
sequenc
antigen
inactiv
viru
product
antiviru
antisera
also
examin
orthomyxovirus
propag
mdck
cell
crimeancongo
hemorrhag
fever
viru
cchfv
cell
lassa
viru
lasv
grown
vero
cell
virus
propag
vero
cell
eighti
ninetyf
percent
confluent
cultur
inocul
multipl
infect
moi
propag
minim
essenti
medium
fetal
bovin
serum
antibioticantimycot
product
number
life
technolog
carlsbad
ca
usa
co
six
ten
day
depend
viru
postinocul
cultur
supernat
collect
centrifug
low
speed
remov
cell
debri
use
viru
prepar
inactiv
accord
previous
describ
method
amt
product
number
ca
number
sigmaaldrich
st
loui
mo
usa
ad
final
concentr
stock
tissu
cultur
infecti
dose
tcid
per
millilit
fivemillilit
aliquot
mixtur
transfer
well
plate
plate
expos
uva
radiat
nm
multipleray
lamp
ultra
violet
product
upland
ca
usa
min
measur
energi
level
radiomet
model
uvab
detector
model
solar
light
glensid
pa
usa
virus
inactiv
similar
manner
includ
cchf
tcid
ml
lassa
josiah
tcid
ml
lasv
middl
east
respiratori
syndrom
coronaviru
jordan
tcid
ml
merscov
uva
radiat
energi
level
amt
requir
fulli
inactiv
venezuelan
equin
enceph
tcid
ml
veev
junin
candid
tcid
ml
junv
rift
valley
fever
tcid
ml
rvfv
ebola
zair
tcid
ml
ebov
junv
rvfv
requir
min
uva
exposur
full
inactiv
ebov
requir
min
uva
exposur
full
inactiv
time
point
aliquot
remov
plate
titer
determin
tcid
aliquot
assay
viabil
viru
isol
vero
cell
use
indirect
immunofluoresc
antibodi
ifa
assay
tcid
assay
adapt
lennett
aliquot
time
point
place
well
plate
contain
vero
cell
confluenc
aliquot
serial
dilut
plate
total
dilut
plate
incub
co
day
cell
monolay
observ
microscop
presenc
cpe
tcid
endpoint
dilut
calcul
reed
muench
method
femal
new
zealand
white
rabbit
charl
river
laboratori
wilmington
usa
receiv
inject
viral
antigen
day
follow
exsanguin
day
day
inject
consist
antigen
emulsifi
complet
freund
adjuv
sigmaaldrich
remain
inject
consist
antigen
emulsifi
incomplet
freund
adjuv
sigmaaldrich
inject
viru
antigen
clarifi
supernat
centrifug
rpm
min
minimum
preinactiv
live
titer
inject
viral
antigen
tcid
ml
virus
test
ifa
aliquot
viru
inactiv
test
time
point
place
cell
cultur
flask
contain
vero
cell
monolay
confluenc
flask
incub
co
day
period
observ
cpe
cultur
allow
incub
maximum
possibl
time
allow
viabl
viru
chanc
replic
detect
level
day
portion
cultur
supernat
place
new
cell
cultur
flask
incub
condit
anoth
day
observ
cpe
result
cell
monolay
scrape
appli
microscop
slide
follow
method
hsiung
briefli
droplet
cell
suspens
appli
slide
allow
dri
room
temperatur
biosafeti
cabinet
bsc
side
fix
min
aceton
permeabil
cell
membran
secur
cell
slide
aceton
fixat
slide
probe
antiviru
antibodi
follow
fluoresceinlabel
goat
antispeci
antibodi
tabl
slide
microscop
screen
detect
cell
exhibit
fluoresc
amount
denv
intern
host
cell
determin
raji
bcell
leukem
cell
line
stabli
express
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
molecul
briefli
live
psoraleninactiv
denv
concentr
pfuml
ad
vbottom
plate
corn
incorpor
ny
usa
contain
per
rajidcsign
cell
h
incub
humidifi
co
incub
cell
wash
fix
permeabil
use
bd
kit
bd
bioscienc
san
jose
ca
usa
follow
manufactur
instruct
fix
cell
stain
monoclon
antibodi
denv
envelop
protein
isotyp
control
bd
bioscienc
follow
fitc
fluorescein
isothiocyan
label
secondari
goatantimous
igg
antibodi
nbacc
cell
treat
viru
serv
neg
control
min
stain
step
cell
sort
facscanto
ii
bd
bioscienc
percent
posit
cell
repres
number
cell
captur
intern
denv
use
dcsign
receptor
sequenc
viru
gene
obtain
genbank
http
wwwncbinlmnihgovgenbank
primer
probe
design
use
integr
dna
technolog
primerquest
primer
probe
design
tool
http
wwwidtdnacomprimerquesthomeindex
oligonucleotid
primer
probe
use
studi
list
tabl
oligonucleotid
primer
probe
synthes
integr
dna
technolog
coralvil
ia
usa
total
rna
extract
psoralentr
cell
supernat
use
qiaamp
viral
rna
mini
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
extract
rna
sampl
elut
volum
rna
puriti
assess
use
qubit
fluoromet
life
technolog
qubit
rna
hs
assay
kit
life
technolog
accord
manufactur
instruct
rna
store
revers
transcript
realtim
pcr
assay
perform
use
superscript
iii
platinum
onestep
qrtpcr
kit
wrox
life
technolog
accord
manufactur
instruct
use
final
concentr
primer
probe
five
microlit
sampl
assay
per
reaction
reaction
consist
cycl
min
revers
transcript
follow
cycl
min
revers
transcriptas
inactiv
cycl
revers
transcript
realtim
pcr
assay
target
includ
notempl
control
test
sampl
revers
transcript
realtim
pcr
reaction
run
appli
biosystem
fast
life
technolog
standard
mode
pcr
amplicon
sequenc
use
appli
biosystem
bigdy
termin
cycl
sequenc
kit
polym
life
technolog
follow
manufactur
instruct
reaction
process
appli
biosystem
genet
analyz
life
technolog
raw
sequenc
analyz
use
sequench
softwar
genecod
ann
arbor
mi
usa
total
rna
prepar
psoraleninactiv
denv
revers
transcrib
use
random
primer
superscript
iii
revers
transcriptas
life
technolog
follow
manufactur
instruct
cdna
amplifi
readytogo
genomiphi
kit
ge
healthcar
piscataway
nj
usa
nextera
xt
librari
illumina
san
diego
ca
usa
prepar
sequenc
illumina
hiseq
platform
follow
manufactur
instruct
protocol
pairedend
bp
illumina
use
join
fragment
known
length
provid
inform
region
repetit
sequenc
dengu
viru
repres
ssrna
viru
previous
inactiv
min
uva
exposur
presenc
psoralen
compound
amt
treat
virus
subject
plaqu
assay
demonstr
inactiv
success
use
antigen
mous
antibodi
product
inactiv
denv
assess
tcid
repeat
tcid
subcultur
ifa
thirti
minut
exposur
uva
light
presenc
amt
suffici
reduc
viabil
level
undetect
tcid
day
cultur
howev
sequenti
passag
subcultur
display
visibl
cpe
second
day
cultur
viru
detect
ifa
signific
chang
earlier
plaqu
assay
data
illustr
rigor
test
method
must
use
confirm
inactiv
forti
minut
exposur
uva
light
presenc
amt
requir
fulli
inactiv
denv
determin
cpe
ifa
two
tenday
sequenti
cultur
tabl
viral
cultur
expos
uv
light
amt
show
reduct
viabil
assess
gener
applic
psoralenmedi
viru
inactiv
repres
virus
seven
famili
expos
uva
presenc
amt
tabl
virus
test
includ
envelop
nonenvelop
virus
spheric
filament
virus
posit
neg
sens
rna
genom
inactiv
achiev
virus
test
rate
titer
reduct
vari
viru
suggest
inactiv
dosedepend
exampl
marv
ebov
requir
exposur
uva
presenc
amt
inactiv
rvfv
denv
figur
viru
treatment
replic
minimum
eight
time
determin
whether
viral
rna
isol
amtinactiv
virus
use
molecular
analys
five
repres
virus
test
compet
reversetranscript
realtim
pcr
inactiv
amt
junin
viru
lassa
viru
arenavirida
rift
valley
fever
viru
bunyavirida
marburg
ebola
virus
filovirida
success
amplifi
use
wellcharacter
previous
publish
assay
see
materi
method
section
five
microlit
fulli
inactiv
junv
produc
cycl
threshold
ct
lasv
rvfv
marv
ebov
inactiv
viru
produc
amplicon
expect
size
amplicon
lasv
junv
rvfv
ebov
success
sequenc
produc
ident
sequenc
untreat
viru
determin
whether
viral
rna
isol
amtinactiv
virus
use
molecular
analys
five
repres
virus
test
compet
reversetranscript
realtim
pcr
inactiv
amt
junin
viru
lassa
viru
arenavirida
rift
valley
fever
viru
bunyavirida
marburg
ebola
virus
filovirida
success
amplifi
use
wellcharacter
previous
publish
assay
see
materi
method
section
five
microlit
fulli
inactiv
junv
produc
cycl
threshold
ct
lasv
rvfv
marv
ebov
inactiv
viru
produc
amplicon
expect
size
amplicon
lasv
junv
rvfv
ebov
success
sequenc
produc
ident
sequenc
untreat
viru
order
fulli
investig
properti
rna
amtinactiv
viru
five
reversetranscript
realtim
pcr
assay
design
target
denv
viru
positivesens
rna
genom
target
rang
base
pair
bp
bp
length
chosen
repres
multipl
gene
untransl
region
genom
five
target
success
amplifi
amtinactiv
denv
photoadduct
present
genom
amt
treatment
inhibitori
revers
transcript
cycl
fluoresc
signal
detect
background
ct
reaction
use
inactiv
viru
similar
ct
reaction
use
live
untreat
viru
tabl
denv
amplicon
success
sequenc
produc
sequenc
ident
produc
denv
treat
amt
data
shown
denv
rna
isol
psoraleninactiv
prepar
reversetranscrib
amplifi
subject
whole
genom
sequenc
illumina
hiseq
use
pairedend
strategi
two
bp
read
approxim
denv
genom
cover
total
read
sequenc
coverag
vari
major
genom
fall
figur
order
fulli
investig
properti
rna
amtinactiv
viru
five
reversetranscript
realtim
pcr
assay
design
target
denv
viru
positivesens
rna
genom
target
rang
base
pair
bp
bp
length
chosen
repres
multipl
gene
untransl
region
genom
five
target
success
amplifi
amtinactiv
denv
photoadduct
present
genom
amt
treatment
inhibitori
revers
transcript
cycl
fluoresc
signal
detect
background
ct
reaction
use
inactiv
viru
similar
ct
reaction
use
live
untreat
viru
tabl
denv
amplicon
success
sequenc
produc
sequenc
ident
produc
denv
treat
amt
data
shown
denv
rna
isol
psoraleninactiv
prepar
reversetranscrib
amplifi
subject
whole
genom
sequenc
illumina
hiseq
use
pairedend
strategi
two
bp
read
approxim
denv
genom
cover
total
read
sequenc
coverag
vari
major
genom
fall
figur
coverag
plot
viru
genom
hiseq
read
map
genom
differ
coverag
differ
area
genom
probabl
relat
rna
fold
bia
librari
prepar
gc
content
rule
hypothesi
area
reduc
coverag
due
photoadduct
format
amt
uva
inactiv
coverag
plot
viru
genom
hiseq
read
map
genom
differ
coverag
differ
area
genom
probabl
relat
rna
fold
bia
librari
prepar
gc
content
rule
hypothesi
area
reduc
coverag
due
photoadduct
format
aminomethyltrioxsalen
amt
uva
inactiv
amtinactiv
denv
previous
shown
bind
panel
monoclon
antibodi
specif
envelop
protein
highli
immunogen
mice
monkey
studi
addit
amtinactiv
virus
test
immunogen
antibodi
gener
rabbit
inocul
live
psoraleninactiv
lasv
cchfv
collect
serum
use
primari
antibodi
ifa
liveviru
infect
tissu
cultur
amtinactiv
lasv
cchfv
elicit
antibodi
specif
recogn
untreat
lasv
cchfv
respect
antibodi
gener
amtinactiv
virus
use
work
dilut
ifa
antibodi
untreat
viru
tabl
indic
titer
similar
serum
suggest
antigen
surfac
live
inactiv
virus
recogn
equal
well
rabbit
immun
system
tabl
antibodi
produc
respons
live
aminomethyltrioxsalen
amt
uva
inactiv
lassa
viru
crimeancongo
hemorrhag
fever
viru
recogn
untreat
virus
type
equal
well
amt
uv
ifa
frequent
use
detect
viral
infect
cultur
cell
use
studi
demonstr
virus
treat
psoralen
fulli
inactiv
inactiv
amt
uva
ebov
prepar
cell
cultur
incub
day
visual
virus
use
ifa
fluoresc
visibl
within
cell
indic
viru
recogn
cellsurfac
receptor
intern
level
fluoresc
significantli
lower
level
observ
posit
control
cultur
contain
live
viru
figur
even
though
similar
amount
viru
inocul
flask
suggest
amount
inactiv
viru
present
increas
incub
subcultur
second
incub
level
fluoresc
low
nearli
indistinguish
neg
control
cultur
two
addit
round
subcultur
incub
total
day
cultur
discern
viru
cultur
inocul
amttreat
ebov
indic
lack
cpe
lack
fluoresc
ifa
figur
indic
viral
replic
taken
place
viru
complet
inactiv
amt
uva
treatment
dengu
viru
enter
cell
via
specif
interact
clathrinco
pit
dcsign
receptor
flow
cytometri
use
establish
virus
inactiv
amt
still
compet
interact
dcsign
cellular
receptor
becom
intern
dcsign
express
cell
line
incub
live
amtinactiv
denv
fac
use
identifi
cell
intern
viru
similar
proport
cell
show
intracellular
fluoresc
incub
amtinactiv
viru
incub
live
denv
figur
suggest
psoraleninactiv
denv
captur
intern
extent
live
denv
host
cell
virus
pagepag
dengu
viru
enter
cell
via
specif
interact
clathrinco
pit
dcsign
receptor
flow
cytometri
use
establish
virus
inactiv
amt
still
compet
interact
dcsign
cellular
receptor
becom
intern
dcsign
express
cell
line
incub
live
amtinactiv
denv
fac
use
identifi
cell
intern
viru
similar
proport
cell
show
intracellular
fluoresc
incub
amtinactiv
viru
incub
live
denv
figur
suggest
psoraleninactiv
denv
captur
intern
extent
live
denv
host
cell
dengu
viru
enter
cell
via
specif
interact
clathrinco
pit
dcsign
receptor
flow
cytometri
use
establish
virus
inactiv
amt
still
compet
interact
dcsign
cellular
receptor
becom
intern
dcsign
express
cell
line
incub
live
amtinactiv
denv
fac
use
identifi
cell
intern
viru
similar
proport
cell
show
intracellular
fluoresc
incub
amtinactiv
viru
incub
live
denv
figur
suggest
psoraleninactiv
denv
captur
intern
extent
live
denv
host
cell
method
viru
inactiv
wide
use
reli
intens
heat
toxic
chemic
render
viru
noninfecti
treatment
also
denatur
crosslink
protein
nucleic
acid
prevent
inactiv
viru
prepar
fulli
effect
antigen
diminish
prevent
amplif
nucleic
acid
pcr
sequenc
denv
previous
shown
inactiv
exposur
uva
light
presenc
amt
studi
method
inactiv
viru
prepar
extend
multipl
viru
famili
method
effect
inactiv
alpha
arena
bunya
corona
filo
flaviand
orthomyxovirus
among
famili
repres
spheric
flexuou
virus
well
positiveand
negativesens
rna
genom
suggest
inactiv
method
success
rna
virus
viru
test
requir
differ
amount
uva
exposur
presenc
amt
inactiv
increas
proport
viru
particl
becam
inactiv
increas
exposur
uva
indic
dosedepend
respons
treatment
rodshap
virus
use
polyprotein
strategi
requir
order
magnitud
microwatt
uva
segment
virus
full
inactiv
known
larg
rang
suscept
amt
uva
inactiv
observ
seem
consist
set
viru
characterist
lead
requir
exposur
amt
uva
full
inactiv
exampl
envelop
spheric
virus
test
requir
low
level
uva
presenc
amt
full
inactiv
cchfv
other
requir
quit
high
level
junv
rvfv
viru
concentr
inactiv
reaction
type
viru
light
condit
uva
intens
paramet
could
conceiv
alter
inactiv
process
like
individu
investig
perform
titrat
experi
defin
appropri
condit
consist
produc
inactiv
chosen
viru
system
method
viru
inactiv
via
uva
exposur
presenc
amt
multipl
benefit
abl
use
amtinactiv
virus
target
antibodi
detect
ifa
fac
antigen
product
new
polyclon
antibodi
polyclon
antibodi
produc
inactiv
viru
work
equal
well
detect
untreat
viru
compar
antibodi
produc
live
viru
prepar
data
taken
togeth
suggest
surfac
protein
inactiv
virus
intact
correctli
orient
allow
full
interact
cell
protein
complex
allow
virus
inactiv
method
use
vaccin
develop
antibodi
gener
research
posit
control
antibodybas
detect
assay
studi
microscopi
nucleic
acid
extract
amtinactiv
virus
noninfecti
suffici
undamag
ebov
junv
lasv
marv
rvfv
achiev
success
detect
reversetranscript
real
time
pcr
viral
nucleic
acid
noninfecti
suffici
undamag
denv
appropri
substrat
real
time
pcr
sanger
nextgener
sequenc
thu
support
method
lower
level
biocontain
libraryprepar
attempt
nextgener
sequenc
use
standard
method
amtinactiv
lasv
veev
unsuccess
may
indic
crosslink
virus
hand
great
allow
nextgener
sequenc
howev
amplicon
base
pair
success
detect
pcr
suggest
number
photoadduct
per
genom
less
per
base
least
case
denv
end
denv
genom
amplifi
readili
intern
target
suggest
photoadduct
concentr
near
end
viru
importantli
method
provid
inact
noninfecti
viru
prepar
may
reliabl
steril
test
without
attempt
remov
toxic
chemic
prepar
method
viral
inactiv
becom
gener
accept
method
inactiv
necessari
perform
multipl
sitespecif
agentspecif
valid
studi
rigor
test
method
multipl
scenario
ensur
prepar
inactiv
method
truli
noninfecti
uva
exposur
time
amt
concentr
requir
inactiv
viru
affect
viral
titer
speciesspecif
may
even
strainspecif
data
need
determin
member
famili
virus
react
treatment
investig
work
close
health
safeti
offic
plan
studi
multipl
method
analysi
statist
signific
number
replic
time
method
could
provid
rapid
access
viru
prepar
genom
materi
pathogen
sampl
quickli
safe
